NCT06827262

Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 1,500 (estimated)
• Sponsor: Boston Scientific Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Compile real-world outcomes of commercially approved Intracept™ Intraosseous Nerve Ablation Systems in the treatment of patients diagnosed with vertebrogenic pain.

Detailed description

The objective of this study is to compile real-world outcomes of commercially approved Intracept™ Intraosseous Nerve Ablation Systems in the treatment of patients diagnosed with vertebrogenic pain.

Conditions

• Chronic Low-back Pain
• Vertebrogenic Pain Syndrome

Interventions

Type	Name	Description
DEVICE	Intracept™ Intraosseous Nerve Ablation	Intracept™ Intraosseous Nerve Ablation for treatment of patients diagnosed with vertebrogenic pain

Timeline

• Start date: 2025-03-26
• Primary completion: 2034-07-01
• Completion: 2034-07-01
• First posted: 2025-02-14
• Last updated: 2026-04-03

Locations

15 sites across 1 country: United States

Regulatory

• FDA-regulated device study